Genor Biopharma’s Merger Progress and Listing Plans

Genor Biopharma Holdings Limited (HK:6998) has released an update.

Genor Biopharma Holdings Limited is progressing with its major proposed merger involving the issuance of consideration shares and a new listing application. The company has extended the deadline for its circular to February 2025, while keeping shareholders informed of developments. However, the merger’s success is contingent on several approvals, including a whitewash waiver and listing application approval.

For further insights into HK:6998 stock, check out TipRanks’ Stock Analysis page.